Terumo BCT announced it has been awarded a In a release, Terumo BCT said it is working with the
The DoD has the option to equally share in the cost of additional safety and efficacy studies of pathogen-reduced whole blood and clinical trials as appropriate for a pre-market approval (PMA) application to
-Under these options, the DoD would fund a maximum of
-Terumo BCT would cost share a maximum of
-Cost sharing is the portion of a project cost not borne by the sponsor.
"The Mirasol system for whole blood provides the potential for safe blood products in environments where this is not possible or practical today. Its use could change the way in which blood is made available to people on a global basis."
The new cost-share contract effort expands the Mirasol system development efforts initiated with the DoD in 2007. The Mirasol system treats blood with a combination of riboflavin (vitamin B2), a non-toxic naturally occurring compound, and ultraviolet light to render a range of disease-causing viruses, such as West Nile virus and HIV, bacteria and parasites less pathogenic.
USAMMDA develops new drugs, vaccines and medical support equipment that enhance readiness, ensure the provision of the highest quality medical care to the DoD, and maximize survival of medical casualties on the battlefield.
Terumo BCT is a company focusing on blood component, therapeutic apheresis and cellular technologies.
((Comments on this story may be sent to email@example.com))
Terumo BCT announced it has been awarded a
In a release, Terumo BCT said it is working with the